ResearcherVanderbilt UniversityNo recent work listed
A. Bapsi Chakravarthy
Matched on ORCID iD 0000-0003-2824-2514; OpenAlex author ID A5043993232, A5103557067. Sources: ClinicalTrials.gov.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 2
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2007: 2 trials · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Co-author DOI 10.3390/cancers14020283↗
- Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Last author DOI 10.1016/j.radonc.2016.04.013↗
- Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-015-9764-6↗
- Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318287885c↗
- 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. Co-author DOI 10.1186/1471-2407-13-155↗
Trials 2
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dana Backlund Cardin · 2 shared papers, 2016–2022 · strength 0.20
- Jordan D. Berlin · 2 shared papers, 2016–2022 · strength 0.20
- Nipun B. Merchant · 4 shared papers, 2013–2016 · strength 0.17
- Paper Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. DOI 10.1016/j.radonc.2016.04.013↗
- Paper Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarc… DOI 10.1007/s12029-015-9764-6↗
- Paper Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic … DOI 10.1097/mpa.0b013e318287885c↗
- Chan Shen · 1 shared paper, 2022 · strength 0.15
- Michael Brian LaPelusa · 1 shared paper, 2022 · strength 0.15
- Marcus Chuan Beng Tan · 1 shared paper, 2022 · strength 0.15
- Cathy Eng · 1 shared paper, 2022 · strength 0.15
- Natalie A. Lockney · 3 shared papers, 2013–2015 · strength 0.12
- Paper Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarc… DOI 10.1007/s12029-015-9764-6↗
- Paper Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic … DOI 10.1097/mpa.0b013e318287885c↗
- Paper 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. DOI 10.1186/1471-2407-13-155↗
- Fen Xia · 3 shared papers, 2013–2015 · strength 0.12
- Paper Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarc… DOI 10.1007/s12029-015-9764-6↗
- Paper Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic … DOI 10.1097/mpa.0b013e318287885c↗
- Paper 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. DOI 10.1186/1471-2407-13-155↗
- Sabrina C. Wentz · 2 shared papers, 2013 · strength 0.07
- Paper Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic … DOI 10.1097/mpa.0b013e318287885c↗
- Paper 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. DOI 10.1186/1471-2407-13-155↗
- Tong Wang · 2 shared papers, 2013 · strength 0.07
- Paper Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic … DOI 10.1097/mpa.0b013e318287885c↗
- Paper 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. DOI 10.1186/1471-2407-13-155↗
- Alexander A. Parikh · 1 shared paper, 2016 · strength 0.05
- Emily W. Chan · 1 shared paper, 2016 · strength 0.05
- Thomas E. Yankeelov · 1 shared paper, 2016 · strength 0.05
- Laura Williams Goff · 1 shared paper, 2016 · strength 0.05
- Sabrina C. Sopha · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.